| Crohn Disease
Avsola vs Cimzia
Side-by-side clinical, coverage, and cost comparison for crohn disease.Deep comparison between: Avsola vs Cimzia with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCimzia has a higher rate of injection site reactions vs Avsola based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cimzia but not Avsola, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Avsola
Cimzia
At A Glance
IV infusion
Every 6-8 weeks
TNF-alpha inhibitor
SC injection
Every 2-4 weeks
TNF-alpha inhibitor
Indications
- Crohn Disease
- Ulcerative Colitis
- Rheumatoid Arthritis
- Arthritis, Psoriatic
- Psoriasis
- Crohn Disease
- Rheumatoid Arthritis
- Juvenile polyarthritis
- Arthritis, Psoriatic
- Ankylosing spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Psoriasis vulgaris
Dosing
Crohn Disease, Ulcerative Colitis, Arthritis, Psoriatic, Psoriasis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 8 weeks maintenance.
Rheumatoid Arthritis 3 mg/kg IV induction at weeks 0, 2, and 6, followed by 3 mg/kg every 8 weeks maintenance, in combination with methotrexate.
Ankylosing Spondylitis 5 mg/kg IV induction at weeks 0, 2, and 6, followed by 5 mg/kg every 6 weeks maintenance.
Crohn Disease 400 mg SC (two 200 mg injections) at Weeks 0, 2, and 4; maintenance 400 mg every 4 weeks.
Rheumatoid Arthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Juvenile polyarthritis Weight-based SC dosing at Weeks 0, 2, and 4, then maintenance every 2 weeks: 100 mg loading / 50 mg maintenance (10 to <20 kg); 200 mg loading / 100 mg maintenance (20 to <40 kg); 400 mg loading / 200 mg maintenance (>=40 kg).
Arthritis, Psoriatic 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks; alternatively, 400 mg every 4 weeks may be considered for maintenance.
Ankylosing spondylitis, Non-Radiographic Axial Spondyloarthritis 400 mg SC at Weeks 0, 2, and 4; then 200 mg every 2 weeks or 400 mg every 4 weeks.
Psoriasis vulgaris 400 mg SC every 2 weeks; for patients <=90 kg, 400 mg at Weeks 0, 2, and 4 followed by 200 mg every 2 weeks may be considered.
Contraindications
- Doses >5 mg/kg in patients with moderate or severe heart failure
- Previous severe hypersensitivity reaction to infliximab products, any inactive ingredient of AVSOLA, or murine proteins
- History of hypersensitivity reaction to certolizumab pegol or any excipient (including angioedema, anaphylaxis, serum sickness, or urticaria)
Adverse Reactions
Most common (>10%) Infections (upper respiratory, sinusitis, pharyngitis), infusion-related reactions, headache, abdominal pain
Serious Pneumonia, cellulitis, abscess, skin ulceration, sepsis, bacterial infection, lymphoma, hepatotoxicity
Postmarketing Neutropenia, agranulocytosis, interstitial lung disease, Stevens-Johnson Syndrome, toxic epidermal necrolysis, acute liver failure, anaphylactic shock, cerebrovascular accidents, myocardial ischemia
Most common (>=8%) Upper respiratory infections (18%), rash (9%), urinary tract infections (8%)
Serious Serious infections, malignancies, heart failure, hypersensitivity reactions, hepatitis B virus reactivation, neurologic reactions, hematologic reactions, autoimmunity, immunosuppression
Postmarketing Systemic vasculitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, new or worsening psoriasis (all subtypes), lichenoid skin reaction, sarcoidosis, melanoma, Merkel cell carcinoma
Pharmacology
TNF-alpha inhibitor; chimeric IgG1kappa monoclonal antibody that neutralizes TNFalpha by binding with high affinity to the soluble and transmembrane forms of TNFalpha, inhibiting binding of TNFalpha with its receptors.
Certolizumab pegol is a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody that selectively neutralizes soluble and membrane-associated human TNF-alpha, a key pro-inflammatory cytokine; it lacks an Fc region and therefore does not fix complement or cause antibody-dependent cell-mediated cytotoxicity in vitro.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Avsola
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Cimzia
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Avsola
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Cimzia
- Covered on 4 commercial plans
- PA (7/8) · Step Therapy (6/8) · Qty limit (7/8)
Humana
Avsola
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Cimzia
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Avsola.
No savings programs available for Cimzia.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AvsolaView full Avsola profile
CimziaView full Cimzia profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.